

PATENT

Attorney Docket No.: RIB-005

(7995/7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Steitz et al.

SERIAL NO.:

10/072,634

GROUP NO.:

2683

FILING DATE:

February 8, 2002

EXAMINER:

Not yet assigned

TITLE:

Ribosome Structure and Protein Synthesis Inhibitors

RECEIVED

Commissioner for Patents Washington, D.C. 20231

APR Z -

Technology Center 2600

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the published patent documents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the published patent documents and publications are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee. AND

Supplemental Information Disclosure Statement Serial No.: 10/072,634

Page 2 of 2

the requisite Statement is below, AND						
the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.						

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R.

 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Date: April 15, 2003 Reg. No.: 38,678

Tel. No.: (617) 248-7317 Fax No.: (617) 248-7100

Respectfully submitted,

Duncan A. Greenhalgh Attorney for Applicants

Testa, Hurwitz, & Thibeault, LLP

High Street Tower 125 High Street

Boston, Massachusetts 02110



FORM PTO - 1449

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: RIB-005

APPLICANTS: Steitz et al.

RECEIVED

SERIAL NO.: 10/072,634

APR 2 . . .

FILING DATE: February 8, 2002 Technology Center 2600

GROUP:

2683

U	.5.	PAI	ENI	DOC	UMEN	15

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	Α4	US-2002-0086308 A1	07/04/02	Steitz et al.			08/03/01
	A5	5,693,791	12/02/97	Truett			04/11/95
	A6	5,866,549	02/02/99	Or et al.			07/03/97
	A7	5,336,768	08/09/94	Albrecht et al.	_		05/24/88
	A8	5,281,703	01/25/94	White et al.			05/07/93
	Α9	5,180,719	01/19/93	White et al.			04/29/91
	A10	6,468,979 B1	10/22/02	Pellacini et al.			07/27/99
	A11	6,437,119 B1	08/20/02	Truett	1		07/17/00
	A12	5,905,144	05/18/99	Truett			09/15/97
	A13	5,466,681	11/14/95	Krivan et al.			01/12/94
	A14	6,380,356 B1	04/30/02	Griffin et al.			12/07/99
	A15	6,446.032 B1	09/03/02	Schimmel			08/14/92

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
	В4	EP 1 186 614 A2	03/13/02	EP			07/16/01		
	B5	EP 1 188 769 A2	03/20/02	EP			08/09/01		
	В6	WO 00/32619	06/08/00	wo			11/24/99		
	В7	WO 95/07271	03/16/95	wo	-		08/16/94		
<u>.</u>	B8	WO 96/18633	06/20/96	wo			12/07/95		
	B9	WO 97/35195	09/25/97	wo		-	03/19/97		

EXAMINER

DATE CONSIDERED



FORM PTO - 1449

SUPPLEMENTAL INFORMATION

DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: RIB-005

APPLICANTS: Steitz et al.

RECEIVED SERIAL NO.: 10/072,634 APR 2 1

FILING DATE: February 8, 2002

Technology Center 2600 2683

		OTHER ART, JOURNAL ARTICLES, ETC.								
	orate)	DOCUMENTS: (Including Author, Title, Place of Publication, Relevant Pages, Date)								
XAM. SIT.	OTHER	CD2 Complexed with an Aminoglycoside								
	C101 Fourmy et al. (1996) "Structure of the A Site of Escherichia coli 16S Ribosomal RNA Complexed with an Aminoglyco									
		Antibiotic" Science 274(5291):1367-1371 Hermann et al. (1999) "Docking of Cationic Antibiotics to Negatively Charged Pockets in RNA Folds" <u>J. Med. Chem.</u>								
	C102	Hermann et al. (1999) "Docking of Cationic Antibiotics to Regarders								
		42(7):1250-1261 Ioannou et al. (1998) "Kinetics of Inhibition of Rabbit Reticulocyte Peptidyltransferase by Anisomycin and Sparsomycin" [22(4):1089-1096]								
	C103	Molecular Pharmacology 53(6):1089-1096 Description of the 3'-Terminal Adenosine of								
		Apribiatics Perturb the Relative Positioning								
	C104	Kirillov et al. (1999) "Peptidyl Transferase Antiolouis 7 et al. (1999) "Peptidyl Transferase Antiolouis 7 et al. (1993) "Peptidyl Tran								
	C105	Decading Center of 10 3 Kibosoffia -								
		Wong et al. (1998) "Specificity of Aminoglycoside Antibiotics for the Asside or the								
ı	C106	Observators & Biology 5(7):597-400								
	C107	European Search Report for Application No. 02255442.2 dated March 6, 2003 European Search Report for Application No. 02255442.2 dated March 6, 2003								
	C10	Hanessian et al. (1984) ""Quantamycin": A Computer-Simulated New-Generation time								
1		Hanessian et al. (1984) Quantum Vince et al. (1975) "Chloramphenicol Binding Site with Analogues of Chloramphenicol and Puromycin" Antimicrobial Vince et al. (1975) "Chloramphenicol Binding Site with Analogues of Chloramphenicol and Puromycin" Antimicrobial								
	C10	Vince et al. (1975) "Chloramphenicol Binding Site Will 7 many Agents and Chemotherapy 8(4):439-443								
\		the angle for Proteins: SAR by North								
	C1	Shuker <i>et al.</i> (1996) "Discovering High-Affinity Liganus for Froeting" Hecker <i>et al.</i> (1993) "Application of Hygromycin A Structure Activity Relationships to the Antibiotic A201A" Bioorganic								
	CI	Hecker et al. (1993) "Application of Frigients" Medicinal Chemistry Letters 3(2):295-298 Medicinal Chemistry Letters 3(2):295-298								
<u></u>		2 (1997) "Dimeric Aminoglycosides: Design, Synthesis and RNA Binding								
1	CI	Letters 7(14):1951-1956								
-		Letters 7(14):1951-1956 Letters 7(14):1951-1956 Holmes et al. (1993) "Novel Dimeric Penicillin Derived Inhibitors of HIV-1 Proteinase: Interaction with the Catalytic Holmes et al. (1993) "Novel Dimeric Penicillin Derived Inhibitors of HIV-1 Proteinase: Interaction with the Catalytic Penistry Letters 3(4):503-508								
		Holmes et al. (1993) "Novel Diffict Cenesistry Letters 3(4):503-508 Aspartates" <u>Bioorganic & Medicinal Chemistry Letters</u> 3(4):503-508 14 Rao et al. (1997) "Tight Binding of a Dimeric Derivative of Vancomycin with Dimeric L-Lys-D-Ala-D-Ala" <u>J. Am. Cher</u>								
-		14 Rao et al. (1997) "Tight Binding of a Dimeric Derivative of Vanconiyen as								
		Soc. 119:10286-10290 Tanihara et al. (1998) "Thrombin-Sensitive Peptide Linkers for Biological Signal-Responsive Drug Release Systems"								
	(Tanihara et al. (1998) "Thrombin-Sensitive repairs Peptides 19(3):421-425								
- 1	1	DATE CONSIDERED								

.60û

APR 1 8 2003 (4)	Application Serial Number			10/072,634			
TID AND CONTINUE	Filing Date			February 8, 2002			
4 MADENIAN	First Named Inventor			Steitz DEOFN 45			
TRANSMITTA	Group Art Unit			RECEIVE			
	Examiner 1	Name	No	Not yet assigned 4PR 2			
FORM		Attorney Docket No.			B-005		
		Patent No.		No	Not applicable I echnology Center		
		Issue Date		No	t applicable		
	ENC	LOSURES (check all that apply)				
Fee Transmittal Form		Copy of Notic	ce to File Missing cation (PTO-1553)		Notice of Appeal to Board of Patent Appeals and Interferences		
☐ Check Attached☐ Copy of Fee Transmittal Form		Formal Drawi	ing(s)		Appeal Brief (in triplicate)		
Amendment/Response		Examination (Request For Continued Examination (RCE)		Status Inquiry		
☐ Preliminary ☐ After Final ☐ Affidavits/declaration(s)	_	Transmittal	i or of Attarna	\boxtimes	Return Receipt Postcard		
Letter to Official Draftsperson including Drawings		Associate Power of Attorney		\boxtimes	Certificate of First Class Mailing under 37 C.F.R. 1.8		
[Total Sheets]	☐ Terminal Disc		claimer		Certificate of Facsimile Transmission under 37 C.F.R. 1.8		
Petition for Extension of Time		Executed Declaration and Power of Attorney for Utility or Design Patent Application			Additional Enclosure(s) (please identify below)		
Supplemental Information Disclosure Statement Form PTO-1449		Small Entity S	statement				
Copies of IDS Citations (A4-A15, B4-B9 and C101- C115)		CD(s) for large table or computer program					
Certified Copy of Priority Document(s)		Amendment After Allowance					
Sequence Listing submission Paper Copy/CD Computer Readable Copy Statement verifying identity of above	(Request for Certificate of Correction Certificate of Correction (in duplicate)					
CORRESPONDENCE ADDRESS			SIGNATURE BLO	СК			
High Stree 125 High S Boston, M Tel. No.: (Fax No.: (Date: April 15, 2003 Reg. No. 38,678 Tel. No.: (617) 248-731 Fax No.: (617) 248-7100		Duncan A. Greenhaleh Attorney for Applicants Testa, Hurwitz & Thibeault, LLP High Street Tower 125 High Street Boston, MA 02110			
2594764							

Application Serial Number



PATENT

Attorney Docket No.: RIB-005

(7995/7)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Steitz et al.

SERIAL NO.:

10/072,634

GROUP NO.:

2683

FILING DATE:

February 8, 2002

EXAMINER:

Not yet assigned

TITLE:

Ribosome Structure and Protein Synthesis Inhibitors

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any documents referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Commissioner for Patents, Washington, DC 20231 on this 15th day of April, 2003.

Commissioner for Patents Washington, D.C. 20231

RECEIVED

Sir:

APR 2 1 19

Technology Center 2600

Submitted herewith are:

- 1. Transmittal Form (1 pg.);
- Supplemental Information Disclosure Statement (2 pgs.); 2.
- 3. Form PTO-1449 (2 pgs.);
- Copies of Documents Cited as A4-A15, B4-B9 and C101-C115; and 4.
- 5. Return Receipt Postcard.